Although data on the role of drugs for the treatment of type 2 diabetes in HCC are limited, there are indications that metformin, sulfonylureas [18], and thiazolidinediones [19] are associated with a reduced risk of HCC, whereas insulin may increase the risk [20]. This evidence concerns the gene INS and hepatocellular carcinoma.